They transferred cultured human IPF fibroblasts into C.B‐17SCID/bg mice and showed that targeting the MAP3K19 enzyme with either siRNA or a small molecule inhibitor could attenuate lung fibrosis in recipient mice.82 Here, MAP3K19 is linked to idiopathic pulmonary fibrosis.